The following is a summary of “Parent Perspectives on Nirsevimab for Their Newborn,” published in the November 2024 issue of ...

A recently approved immunization drug is helping to limit the severity of a respiratory disease that afflicts young children ...

Seasonal maternal RSV vaccination may be cost-effective, as well as nirsevimab, particularly for those with higher risks ...

Seasonal maternal RSV vaccination may be cost-effective, particularly for those with higher risks. HealthDay News — Seasonal maternal respiratory syncytial virus (RSV) vaccination and nirsevimab ...

RSV is the most common cause of hospitalization in infants under 1 year old. The infection can spread to the lungs and cause ...

Learn about this vaccine that protects against a common seasonal virus that can sometimes cause severe disease, with info on ...

AstraZeneca and Sanofi now have the data they need in hand to press ahead with regulatory filings next year for nirsevimab, an antibody designed to prevent respiratory syncytial virus (RSV ...

IDWeek 2024 was held at the Los Angeles Convention Center in Downtown Los Angeles, CA, USA, from 16–19 October. Phoebe Hall ...

During the 2023-2024 respiratory virus season, 17.8% of pregnant women aged 18 to 49 were vaccinated, and 51.2% of infants were protected from RSV through either maternal vaccination or administration ...